187. Breast. 2018 Jun;39:151-152. doi: 10.1016/j.breast.2018.03.003. Epub 2018 Mar 17.Reply to the letter "Body mass index and clinical outcomes in trastuzumab-treatedmetastatic breast cancer patients: An alternative explanation for the lack ofassociation".Poletto E(1), Martel S(2), Lambertini M(3), Puglisi F(4).Author information: (1)Department of Medical Oncology, Azienda Sanitaria Universitaria Integrata diUdine, Udine, Italy.(2)Département d'hémato-oncologie, CISSS Montérégie centre/HôpitalCharles-Lemoyne, centre affilié de l'Université de Sherbrooke, Greenfield Park,QC, Canada.(3)Department of Medical Oncology, Institut Jules Bordet, Université Libre deBruxelles (U.L.B.), Brussels, Belgium. Electronic address:matteo.lambertini85@gmail.com.(4)Department of Medical Oncology, Azienda Sanitaria Universitaria Integrata diUdine, Udine, Italy; Department of Clinical Oncology, Unit of Medical Oncologyand Cancer Prevention, CRO Aviano National Cancer Institute, Aviano, Italy;Department of Medicine, University of Udine, Italy.DOI: 10.1016/j.breast.2018.03.003 PMID: 29555407 